EBGI Category: Colon
-
Do Not Extend Interval Between CRC Screening Colonoscopies from 10 to 15 Years: Perils of Administrative Databases
American College of Gastroenterology / EBGI Articles / Colon / Do Not Extend Interval Between CRC Screening Colonoscopies from 10 to 15 Years: Perils of Administrative DatabasesDo Not Extend Interval Between CRC Screening Colonoscopies from 10 to 15 Years: Perils of Administrative Databases Philip Schoenfeld, MD,…
-
Multi-Target Stool RNA Test for CRC Screening: When Should You Use It?
American College of Gastroenterology / EBGI Articles / Colon / Multi-Target Stool RNA Test for CRC Screening: When Should You Use It?Multi-Target Stool RNA Test for CRC Screening: When Should You Use It? Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief (Emeritus),…
-
Making Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel Preparation
American College of Gastroenterology / EBGI Articles / Colon / Making Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel PreparationMaking Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel Preparation Ahmad Abu-Heija, MBBS Consultant…
-
AGA-ACG Clinical Practice Guideline on Chronic Idiopathic Constipation Treatments: Parsing Benefits and Risks
American College of Gastroenterology / EBGI Articles / Colon / AGA-ACG Clinical Practice Guideline on Chronic Idiopathic Constipation Treatments: Parsing Benefits and RisksThis evidence-based summary reviews the new clinical practice guideline from the ACG and AGA on the pharmacological management of chronic idiopathic constipation.
-
Donor Stool Product for FMT Decreases Recurrent C. difficile infection: RBX2660 Is the First FDA-Approved Live Biotherapeutic Product
American College of Gastroenterology / EBGI Articles / Colon / Donor Stool Product for FMT Decreases Recurrent C. difficile infection: RBX2660 Is the First FDA-Approved Live Biotherapeutic ProductDonor Stool Product for FMT Decreases Recurrent Clostridioides difficile Infection: RBX2660 Is the First FDA-Approved Live Biotherapeutic Product Colleen R.…
-
SER-109, an Oral Microbiome Therapy, Decreases Recurrent Clostridiodes difficile Infection
American College of Gastroenterology / EBGI Articles / Colon / SER-109, an Oral Microbiome Therapy, Decreases Recurrent Clostridiodes difficile InfectionSER-109, an Oral Microbiome Therapy, Decreases Recurrent Clostridiodes difficile Infection Jessica R. Allegretti, MD, MPH Associate Director, Crohn’s and Colitis…